next »

[Andy Battaglia]

Big News about gene therapy.

http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-eu-conditional-marketing-authorization?fbclid=IwAR1l2gasMyEgZEDW01qPytvFOlUHXJF3oQntIitkCXLpRoGIL-dy7_A73Zo

bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)

[sagar1]

thanks for the update. Lets see whats the cost of treatment.

[sagar1]

Bluebird bio has come out with a price tag of USD 1.80 million. This is a huge price tag, so patients in Asian countries can't afford to have this treatment

[Andy Battaglia]

I would expect the eventual price to be lower in Asia, just as it is with BMT. IF not, they won't get anywhere in the Asian markets.

[sanjuna]

Hi I like to know when this treatment will be available in Asian country, particularly in india.

[Andy Battaglia]

It's tough to predict when this will become available outside of Europe. It will be submitted for approval in the US next year. After approval, there is a period when the manufacturing process and the distribution network is being set up, so approval won't mean immediate access at first. Hopefully, prices will be adjusted for the Asian market when it does become available.